AUTHOR=Wang Shuo , Ji Yongpeng , Chen Yanyun , Du Peng , Cao Yudong , Yang Xiao , Ma Jinchao , Yu Ziyi , Yang Yong 

TITLE=The Values of Systemic Immune-Inflammation Index and Neutrophil–Lymphocyte Ratio in the Localized Prostate Cancer and Benign Prostate Hyperplasia: A Retrospective Clinical Study

JOURNAL=Frontiers in Oncology

VOLUME=Volume 11 - 2021

YEAR=2022

URL=https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2021.812319

DOI=10.3389/fonc.2021.812319

ISSN=2234-943X

ABSTRACT=<sec><title>Purpose</title><p>To evaluate the diagnostic values of systemic immune-inflammation index (SII) and neutrophil–lymphocyte ratio (NLR) in patients with localized prostate cancer (PCa).</p></sec><sec><title>Methods</title><p>Between January 2014 and December 2019, 117 patients with benign prostate hyperplasia (BPH) and 278 patients with localized PCa who underwent radical prostatectomy (RP) were included in this study. The inflammatory markers including SII, NLR, platelet–lymphocyte ratio (PLR), lymphocyte–monocyte ratio (LMR), lymphocyte ratio (LR), neutrophil ratio (NR), mean platelet volume (MPV), and red cell distribution (RDW) of these two groups were examined and analyzed. ROC curve analysis was performed to assess the discriminative ability of inflammatory markers and their combination with tPSA for PCa. The binary logistic regression model was used to evaluate the association between significant inflammatory markers and risk of PCa.</p></sec><sec><title>Results</title><p>The pathological results from RP specimen comprised 72 (25.90%) patients with pT1, 168 (60.43%) patients with pT2, and 38 (13.67%) patients with pT3. According to Student’s <italic>t</italic> test, patients with PCa had higher NLR (<italic>p</italic> = 0.034), SII (<italic>p</italic> = 0.008), and NR (<italic>p</italic> = 0.004), and lower LR (<italic>p</italic> = 0.025), MPV (<italic>p</italic> = 0.003), and TPV (<italic>p</italic> = 0.022) compared with patients with BPH; the distribution of age, PLR, LMR, RDW, f/t PSA ratio, and BMI did not show any significant differences. The AUC for NLR, SII, NR, and tPSA was 0.697 (<italic>p</italic> = 0.015), 0.719 (<italic>p</italic> &lt; 0.001), 0.647 (<italic>p</italic> = 0.009), and 0.708 (<italic>p</italic> &lt; 0.001), with threshold values of 1.6, 471.86, 65.15%, and 12.89 ng/ml, respectively. Patients were divided into two groups according to the threshold values, respectively. By using the multivariable logistic regression models, NLR ≥ 1.6 (OR, 2.731; 95% CI, 0.937–7.961, <italic>p</italic> = 0.042), SII ≥ 471.86 (OR, 1.274; 95% CI 0.473–3.433; <italic>p</italic> = 0.033), and PSA ≥ 12.89 ng/ml (OR, 1.443; 95% CI, 0.628–3.944; <italic>p</italic> = 0.014) were independent risk factors associated with PCa. The AUC for combination of NLR, SII, and NR with tPSA was 0.705 (<italic>p</italic> &lt; 0.001), 0.725 (<italic>p</italic> &lt; 0.001), and 0.704 (<italic>p</italic> &lt; 0.001), respectively.</p></sec><sec><title>Conclusion</title><p>This study demonstrated that SII, NLR, and NR were all independent risk factors of PCa. These factors alone could provide better screen methods for PCa before biopsy. In addition, SII is a more powerful tool among these three inflammatory markers associated with PCa. Besides, combination of SII and NLR with tPSA had not much advantage compared with themselves alone.</p></sec>